Your browser doesn't support javascript.
Aesthetic Office Disaster Preparedness and Response Plan
J Drugs Dermatol ; 20(1):10-16, 2021.
Article in English | PubMed | ID: covidwho-1006678
ABSTRACT
The coronavirus pandemic (COVID-19) has served as a call-to-arms in preparing practices for the next disaster whether it is another infectious disease or a flood, hurricane, earthquake, a sustained power outage, or something else. A group of predominantly core aesthetic physicians discussed the various aspects of their office procedures that warrant consideration in a proactive approach to the next pandemic/disaster-related event. This guide does not set a standard of practice but contains recommendations that may avoid some of the "lessons learned" with the COVID-19 pandemic. In this paper, the board-certified core aesthetic physicians classified these recommendations into four generalized areas Practice Management;Supplies and Inventory;Office Staffing Considerations and Protocols;and Patient Management Strategies. Proactive strategies are provided in each of these categories that, if implemented, may alleviate the processes involved with an efficient office closure and reopening process including, in the case of COVID-19, methods to reduce the risk of transmission to doctors, staff, and patients. These strategies also include being prepared for emergency-related notifications of employees and patients;the acquisition of necessary equipment and supplies such as personal protective equipment;and the maintenance and accessibility of essential data and contact information for patients, vendors, financial advisors, and other pertinent entities.J Drugs Dermatol. 2021;20(1)10-16. doi10.36849/JDD.2021.5803.

Full text: Available Collection: Databases of international organizations Database: PubMed Language: English Journal: J Drugs Dermatol Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: PubMed Language: English Journal: J Drugs Dermatol Year: 2021 Document Type: Article